ProBioGen Successfully Completes CMC Development Milestones for Marea’s Promising Acromegaly Therapeutic
Berlin, Germany - March 6, 2025 ProBioGen and Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop..
%20kooperieren%20im%20Berlin%20Center%20for%20Gene%20und%20Cell%20Therapies%20(BC%20GCT)-3.jpeg)
ProBioGen to Lead GMP Manufacturing Operations at Berlin Center for Gene and Cell Therapies (BC GCT)
Sep 16, 2025
%20kooperieren%20im%20Berlin%20Center%20for%20Gene%20und%20Cell%20Therapies%20(BC%20GCT)-1.jpeg)
ProBioGen und das Berlin Institute of Health in der Charité (BIH) kooperieren im Berlin Center for Gene und Cell Therapies (BC GCT)
Sep 16, 2025
ProBioGen Enters Agreement with Polpharma Biologics to Provide High-Performance Cell Line Development Services
May 7, 2025
ProBioGen Successfully Completes CMC Development Milestones for Marea’s Promising Acromegaly Therapeutic
Mar 6, 2025
ProBioGen Launches New Website to Enhance User Experience and Streamline Access to Expanded Portfolio
Feb 4, 2025
Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development
Nov 5, 2024
ModeX Therapeutics Leverages ProBioGen's Expertise for Accelerated COVID-19 Antibody Development
May 29, 2024
ProBioGen and DIOSynVax Partner to Manufacture Groundbreaking Multivalent Vaccine for Hemorrhagic Fever
Mar 27, 2024
ProBioGen Partners with MAPP BIOPHARMACEUTICAL, INC. for Groundbreaking Development of Afucosylated Antibody Against Marburg Virus Disease Using GlymaxX Technology
Mar 13, 2024
